Peter Adams

Cooley represented the former board of directors of Sequenom, a molecular diagnostics company, in a nearly seven-year-long securities class action brought by the company’s former investors.

Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley secured a win on behalf of Qualcomm when the Ninth Circuit affirmed the district court's dismissal of a securities class action alleging that the company misled working in good faith to negotiate a potential sale of the company to rival chipmaker Broadcom, based in Singapore, while working behind scenes to scuttle the deal before the Committee on Foreign Investment in the United States. Mr. Fukumura argued at both the trial and appellate court levels which found that plaintiffs failed to plead falsity, scienter and loss causation.